Article
From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive
12 Aug 2025
Abstract excerpt
YCT-529 reversibly reduces sperm counts to infertility levels in mice and non-human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
